Genmab A/S Sponsored ADR (NASDAQ:GMAB) Shares Sold by US Bancorp DE

Key Points

• US Bancorp DE sold 34.6% of its holdings in Genmab A/S during Q1, reducing its stake to 107,553 shares valued at $2.1 million.
• Several hedge funds increased their positions in Genmab A/S, with Two Sigma Investments LP raising its stake by 122.2%, now owning 1.7 million shares valued at $35.6 million.
• Genmab reported $715 million in revenue for the last quarter, surpassing the consensus estimate, and has a current consensus rating of "Moderate Buy" with a target price of $37.80.

US Bancorp DE lowered its stake in Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) by 34.6% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 107,553 shares of the company's stock after selling 56,995 shares during the period. US Bancorp DE's holdings in Genmab A/S were worth $2,106,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Marotta Asset Management increased its position in shares of Genmab A/S by 5.8% in the 1st quarter. Marotta Asset Management now owns 13,532 shares of the company's stock worth $265,000 after purchasing an additional 739 shares during the last quarter. Gallacher Capital Management LLC increased its position in shares of Genmab A/S by 6.8% in the 1st quarter. Gallacher Capital Management LLC now owns 14,346 shares of the company's stock worth $281,000 after purchasing an additional 915 shares during the last quarter. Laird Norton Wetherby Wealth Management LLC increased its position in shares of Genmab A/S by 17.3% in the 4th quarter. Laird Norton Wetherby Wealth Management LLC now owns 13,711 shares of the company's stock worth $286,000 after purchasing an additional 2,023 shares during the last quarter. NewEdge Advisors LLC grew its position in shares of Genmab A/S by 12.7% during the 4th quarter. NewEdge Advisors LLC now owns 19,304 shares of the company's stock valued at $403,000 after buying an additional 2,171 shares during the last quarter. Finally, Barclays PLC grew its position in shares of Genmab A/S by 1,072.8% during the 4th quarter. Barclays PLC now owns 2,498 shares of the company's stock valued at $52,000 after buying an additional 2,285 shares during the last quarter. Institutional investors own 7.07% of the company's stock.

Genmab A/S Stock Up 2.7%

NASDAQ GMAB traded up $0.57 on Tuesday, hitting $21.65. The stock had a trading volume of 344,656 shares, compared to its average volume of 1,447,395. Genmab A/S Sponsored ADR has a one year low of $17.24 and a one year high of $27.94. The stock has a market cap of $13.89 billion, a price-to-earnings ratio of 10.89, a P/E/G ratio of 6.35 and a beta of 0.95. The company's 50-day moving average is $21.73 and its two-hundred day moving average is $20.86.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $0.54 EPS for the quarter, topping the consensus estimate of $0.39 by $0.15. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%. The firm had revenue of $925.00 million during the quarter, compared to analysts' expectations of $5.77 billion. On average, sell-side analysts anticipate that Genmab A/S Sponsored ADR will post 1.45 earnings per share for the current year.

Analyst Ratings Changes

GMAB has been the subject of a number of recent research reports. Wall Street Zen raised shares of Genmab A/S from a "hold" rating to a "buy" rating in a research report on Monday, July 28th. Truist Financial boosted their price objective on shares of Genmab A/S from $45.00 to $46.00 and gave the company a "buy" rating in a research report on Tuesday, July 8th. One research analyst has rated the stock with a sell rating, three have given a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $37.80.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.